Reduction in Intestinal Colonization and Invasion of Internal Organs After Challenge by Homologous and Heterologous Serovars of Salmonella enterica Following Vaccination of Chickens with a Novel Trivalent Inactivated Salmonella Vaccine.

A novel inactivated vaccine comprising three serovars of Salmonella enterica (Enteritidis, serogroup O:9; Typhimurium, serogroup O:4; Infantis, serogroup O:7) grown under conditions of iron restriction and adjuvanted with aluminium hydroxide was evaluated for efficacy following challenge by homologous and heterologous serovars. Chickens were vaccinated at six and ten weeks of age by the intramuscular route and challenged four to nine weeks after the second vaccination with serovars belonging to serogroup O:9 (Enteritidis), O:4 (Typhimurium and Heidelberg), O:7 (Infantis and Virchow) and O:8 (Hadar). All vaccinated birds produced a marked systemic antibody response against each of the component vaccine antigens by the time of challenge. Significant reductions in both colonization of the intestinal tract and invasion of internal organs was observed in vaccinated birds compared with non-vaccinated controls, irrespective of the challenge serovar. The findings suggest that broad serovar protection within the constitutive serogroups of an inactivated multi-valent vaccine is possible and could therefore play an important role in future Salmonella control programmes. Research Highlights - Novel inactivated trivalent Salmonella chicken vaccine was developed and tested, - Vaccine induced marked systemic antibody response against all vaccine antigens, - Significant reductions in intestinal tract colonisation and internal organ invasion, - Vaccine efficacy demonstrated against homologous and heterologous serovars.